U.S. markets closed

SIGA Technologies, Inc. (SIGA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.77+0.10 (+1.50%)
At close: 4:00PM EDT
6.77 0.00 (0.00%)
After hours: 04:19PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close6.67
Bid6.37 x 800
Ask6.77 x 1000
Day's Range6.55 - 6.85
52 Week Range5.66 - 7.85
Avg. Volume337,453
Market Cap508.269M
Beta (5Y Monthly)0.64
PE Ratio (TTM)12.42
EPS (TTM)0.55
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
1% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SIGA Technologies Inc.
    INVA: Lowering target price to $16.00INNOVIVA INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    22 days agoArgus Research
View more
  • GlobeNewswire

    SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®

    NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its 75A50118C00019 (19C) contract with Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX® treatment courses valued at approximately $

  • GlobeNewswire

    SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021

    NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore, Maryland. Dr. Gomez will be giving a presentation "Antiviral Drugs: Adapting Capabilities for an Effective Response to Future Epidemic Outbreaks" and will join a panel with leadership from Health and Human Services

  • GlobeNewswire

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021

    - Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter – - Authorization of Additional $50 Million Share Repurchase Program - - Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2021. “SIGA’s second quarter financial results show a steady continuing posi